IMPACC-MEDVAMC

这项补充建议的目的是了解气道疾病的成因，从而改善 诊断和治疗这些常见的和使人衰弱的人类疾病。免疫分型 COVID-19队列研究（IMPACC）中的评估协调了一个全国性的多机构联盟， 从住院的COVID-19感染者中收集详细的临床数据和生物样本， 识别与临床病程相关的免疫特征/分子生物标志物的目标， 临床干预和决策的优先顺序。此补充支持贝勒学院 医学和迈克尔E。DeBakey VA医疗中心（MEDVAMC）参与IMPACC，以促进 新冠肺炎住院患者的筛查和入组。建议的补充研究在范围内 母基金R 01 AI 135803，中度至重度哮喘的真菌发病机制。本补充 提交用于临床数据和样本采集/处理，范围将限于 确诊感染COVID-19的患者。根据MEDVAMC对COVID-19疾病的预测趋势，我们 预计6个月内可招募多达50名COVID-19患者。由于报名者将接受随访， 预算延长至18个月。收集的数据将包括主要数据和次要数据 临床和机制终点以及探索性临床和机制终点。

The objective of this supplement proposal is to understand the causes of airway diseases and thereby improve diagnosis and therapy of these common and debilitating of human ailments. The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical interventions and decision making. This supplement supports Baylor College of Medicine's and the Michael E. DeBakey VA Medical Center's (MEDVAMC) participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. The proposed supplement research is within the scope of parent grant R01 AI135803, Fungal Pathogenesis of Moderate to Severe Asthma. This supplement is submitted for the purpose of Clinical data and sample collection/processing and the scope will be confined to patients confirmed to have COVID-19. Based on projected trends in COVID-19 disease in MEDVAMC, we estimate that up to 50 COVID-19 patients can be enrolled within 6 months. As enrollees will be followed for up to one year, the budget extends to 18 months. Data to be collected will consist of both primary and secondary clinical and mechanistic endpoints as well as exploratory clinical and mechanistic endpoints.